Sami-Sabinsa Group Limited-Dobaspet Unit

5 records, newest first. Each line links to the FDA page it came from.

Refusal charges, in plain English

• UNAPPROVED3 refused lines

  Unapproved new drug

  The product appeared to be a new drug within the meaning of section 201(p) of the FD&C Act without an approved New Drug Application. FDA can apply this charge to a food or supplement whose labeling presents it for drug uses.

Questions about Sami-Sabinsa Group Limited-Dobaspet Unit

Is Sami-Sabinsa Group Limited-Dobaspet Unit on an FDA import alert?

No listing for Sami-Sabinsa Group Limited-Dobaspet Unit appears in the FDA import alerts SupplierRadar checked on October 26, 2026. Country-wide alerts may still apply to its products; see the India page.

Has FDA refused shipments from Sami-Sabinsa Group Limited-Dobaspet Unit?

Yes. FDA refused 3 shipment lines from Sami-Sabinsa Group Limited-Dobaspet Unit on March 31, 2026. The most recent, on March 31, 2026, was herbals & botanicals (not teas), n.e.c., charged as UNAPPROVED (unapproved new drug).

Why did FDA refuse Sami-Sabinsa Group Limited-Dobaspet Unit's shipments?

The most frequent charge is UNAPPROVED (unapproved new drug, 3 lines).

When was Sami-Sabinsa Group Limited-Dobaspet Unit last inspected by FDA?

FDA's most recent inspection of Sami-Sabinsa Group Limited-Dobaspet Unit with a final classification is dated April 2, 2024 and was classified VAI (Voluntary Action Indicated).

What is Sami-Sabinsa Group Limited-Dobaspet Unit's FEI number?

Sami-Sabinsa Group Limited-Dobaspet Unit's FDA Establishment Identifier (FEI) is 3008250909.